tetano
Editor, Senior Moderator
Microbiol Spectr
. 2023 Jan 5;e0237622.
doi: 10.1128/spectrum.02376-22. Online ahead of print.
Longevity and Neutralizing Capacity of IgG Antibodies against SARS-CoV-2 Generated by the Application of BNT162b2, AZD1222, Convidecia, Sputnik V, and CoronaVac Vaccines: a Cohort Study in the Mexican Population
Larissa Fernandes-Matano[SUP] #[/SUP][SUP] 1 2 [/SUP], Angel Gustavo Salas-Lais[SUP] #[/SUP][SUP] 3 [/SUP], Concepción Grajales-Muñiz[SUP] 4 [/SUP], Mauricio Hernández-Ávila[SUP] 5 [/SUP], Yonathan Omar Garfias-Becerra[SUP] 6 7 [/SUP], Mario César Rodríguez-Sepúlveda[SUP] 5 [/SUP], Carlos Segura-Sánchez[SUP] 5 [/SUP], Daniel Montes-Herrera[SUP] 3 [/SUP], Denisse Mendoza-Sánchez[SUP] 3 [/SUP], Javier Angeles-Martínez[SUP] 3 [/SUP], Andrea Santos Coy-Arechavaleta[SUP] 3 [/SUP], Julio Elías Alvarado-Yaah[SUP] 3 [/SUP], Clara Esperanza Santacruz-Tinoco[SUP] 8 [/SUP], Eva Ramón-Gallegos[SUP] 2 [/SUP], José Esteban Muñoz-Medina[SUP] 1 [/SUP]
Affiliations
Abstract
The WHO has approved the use of several vaccines during the COVID-19 pandemic; experience over the last 2 years has indicated that dose demand can only be covered using more than one design. Therefore, having scientific evidence of the performance of the different vaccines applied in a country is highly relevant. In Mexico, 5 vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were used, allowing a cohort study to analyze the generation of anti-S1/S2 IgG antibodies and anti-RBD antibodies with neutralizing activity at 0, 21, 90, and 180 days after vaccination. Five groups of participants were formed on the basis of the type of vaccine received and were divided on the basis of whether they previously had or did not have COVID-19. After completing the vaccination schedule, the seroprevalence was 95.5, 97.5, 81.0, 95.2, and 90.0% (BNT162b2, AZD1222, Convidecia, Sputnik V, and CoronaVac, respectively). Among the participants without COVID-19 prior to vaccination, the largest amount of antibodies in the 90-day period was observed in the BNT162b2 group, and the amount of antibodies in the Sputnik V group decreased the least over time. Even though the percentages of seroconversion obtained in this study were lower than those currently reported in other parts of the world, the tested vaccines are able, in most cases, to induce a good production of IgG antibodies anti-S1/S2 and neutralizing capacity. The fact that there are people who have not produced antibodies during the study leaves open some questions that must be investigated to avoid the appearance of serious cases of COVID-19. IMPORTANCE Since the start of the vaccination programs against COVID-19 in 2020, it was evident that due to global shortages, the demand for the dose required in Mexico could only be covered by acquiring different vaccines. Therefore, determining the effectiveness of these and the longevity of acquired immunity is extremely important in a scenario where SARS-CoV-2 circulation becomes endemic and booster doses are required periodically. Our data reveal significant differences both in the generation of antibodies as well as in their longevity for the vaccines applied in the country but suggest that, in general, the Mexican population can reach a high capacity to neutralize the virus, therefore, regarding less the variant for which they were designed.
Keywords: antibodies; longevity; vaccines.
. 2023 Jan 5;e0237622.
doi: 10.1128/spectrum.02376-22. Online ahead of print.
Longevity and Neutralizing Capacity of IgG Antibodies against SARS-CoV-2 Generated by the Application of BNT162b2, AZD1222, Convidecia, Sputnik V, and CoronaVac Vaccines: a Cohort Study in the Mexican Population
Larissa Fernandes-Matano[SUP] #[/SUP][SUP] 1 2 [/SUP], Angel Gustavo Salas-Lais[SUP] #[/SUP][SUP] 3 [/SUP], Concepción Grajales-Muñiz[SUP] 4 [/SUP], Mauricio Hernández-Ávila[SUP] 5 [/SUP], Yonathan Omar Garfias-Becerra[SUP] 6 7 [/SUP], Mario César Rodríguez-Sepúlveda[SUP] 5 [/SUP], Carlos Segura-Sánchez[SUP] 5 [/SUP], Daniel Montes-Herrera[SUP] 3 [/SUP], Denisse Mendoza-Sánchez[SUP] 3 [/SUP], Javier Angeles-Martínez[SUP] 3 [/SUP], Andrea Santos Coy-Arechavaleta[SUP] 3 [/SUP], Julio Elías Alvarado-Yaah[SUP] 3 [/SUP], Clara Esperanza Santacruz-Tinoco[SUP] 8 [/SUP], Eva Ramón-Gallegos[SUP] 2 [/SUP], José Esteban Muñoz-Medina[SUP] 1 [/SUP]
Affiliations
- PMID: 36602375
- DOI: 10.1128/spectrum.02376-22
Abstract
The WHO has approved the use of several vaccines during the COVID-19 pandemic; experience over the last 2 years has indicated that dose demand can only be covered using more than one design. Therefore, having scientific evidence of the performance of the different vaccines applied in a country is highly relevant. In Mexico, 5 vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were used, allowing a cohort study to analyze the generation of anti-S1/S2 IgG antibodies and anti-RBD antibodies with neutralizing activity at 0, 21, 90, and 180 days after vaccination. Five groups of participants were formed on the basis of the type of vaccine received and were divided on the basis of whether they previously had or did not have COVID-19. After completing the vaccination schedule, the seroprevalence was 95.5, 97.5, 81.0, 95.2, and 90.0% (BNT162b2, AZD1222, Convidecia, Sputnik V, and CoronaVac, respectively). Among the participants without COVID-19 prior to vaccination, the largest amount of antibodies in the 90-day period was observed in the BNT162b2 group, and the amount of antibodies in the Sputnik V group decreased the least over time. Even though the percentages of seroconversion obtained in this study were lower than those currently reported in other parts of the world, the tested vaccines are able, in most cases, to induce a good production of IgG antibodies anti-S1/S2 and neutralizing capacity. The fact that there are people who have not produced antibodies during the study leaves open some questions that must be investigated to avoid the appearance of serious cases of COVID-19. IMPORTANCE Since the start of the vaccination programs against COVID-19 in 2020, it was evident that due to global shortages, the demand for the dose required in Mexico could only be covered by acquiring different vaccines. Therefore, determining the effectiveness of these and the longevity of acquired immunity is extremely important in a scenario where SARS-CoV-2 circulation becomes endemic and booster doses are required periodically. Our data reveal significant differences both in the generation of antibodies as well as in their longevity for the vaccines applied in the country but suggest that, in general, the Mexican population can reach a high capacity to neutralize the virus, therefore, regarding less the variant for which they were designed.
Keywords: antibodies; longevity; vaccines.